Aegis reiterated their buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) in a research report released on Wednesday, May 17th. The brokerage currently has a $11.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, May 15th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a buy rating in a report on Thursday, May 11th. Maxim Group restated a buy rating on shares of Inovio Pharmaceuticals in a report on Thursday, May 11th. Nomura reissued a buy rating and issued a $40.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Jefferies Group LLC reissued a neutral rating and issued a $38.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $19.16.

Inovio Pharmaceuticals (INO) opened at 7.47 on Wednesday. Inovio Pharmaceuticals has a one year low of $5.83 and a one year high of $11.61. The firm’s market capitalization is $557.46 million. The stock has a 50 day moving average price of $6.90 and a 200-day moving average price of $6.79. Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The company had revenue of $10.40 million during the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS. On average, analysts predict that Inovio Pharmaceuticals will post ($1.10) earnings per share for the current fiscal year.

Inovio Pharmaceuticals (INO) opened at 7.47 on Wednesday. Inovio Pharmaceuticals has a one year low of $5.83 and a one year high of $11.61. The firm’s market capitalization is $557.46 million. The stock has a 50 day moving average price of $6.90 and a 200-day moving average price of $6.79. In related news, CEO Jong Joseph Kim sold 147,180 shares of the stock in a transaction on Friday, March 31st. The shares were sold at an average price of $6.54, for a total transaction of $962,557.20. Following the completion of the transaction, the chief executive officer now owns 2,164,887 shares in the company, valued at $14,158,360.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Morton Collins bought 21,300 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Monday, March 27th. The shares were acquired at an average price of $6.25 per share, with a total value of $133,125.00. Following the acquisition, the director now directly owns 142,291 shares of the company’s stock, valued at approximately $889,318.75. The disclosure for this purchase can be found here. 9.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $104,000. Advisor Group Inc. boosted its stake in shares of Inovio Pharmaceuticals by 729.6% in the third quarter. Advisor Group Inc. now owns 12,677 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 11,149 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares in the last quarter. Keybank National Association OH boosted its stake in shares of Inovio Pharmaceuticals by 6.9% in the fourth quarter. Keybank National Association OH now owns 30,242 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 1,950 shares in the last quarter. Finally, ARK Investment Management LLC purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $217,000. Institutional investors and hedge funds own 28.72% of the company’s stock. About Inovio Pharmaceuticals